Recurrent and Refractory Cancer Treatment Program

The Recurrent and Refractory Cancer Treatment Program is dedicated to working with patients whose cancers have recurred or are not responding to treatments.

Physical Therapy During Cancer Treatment

CHOC provides physical therapy during and after cancer treatment to help with difficulty doing daily activities resulting from cancer treatment.

Outpatient Cancer Treatment Services

We strive to treat patients as much as possible on an outpatient basis so that they can focus on getting better in the comfort of their own homes and maintain as normal a lifestyle that their treatment will allow.

Cancer Diagnostic Tests

We are proud to be able to provide our oncology patients with everything they will need without having to leave CHOC.

CHOC Oncology Patient Ball

Experience an unforgettable night of fun and community for teen and young adult patients with cancer at the CHOC Oncology Patient Ball.

Current State of Adolescent and Young Adult Cancer

Oncology Clinical Trial: Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Clinical Trial Protocol # ALTE07C1 | Survivorship | Contact (714) 509-8646

How immunotherapy works to treat your child’s cancer

Dr. Ashley Plant, pediatric oncologist, discusses how the immune system and immunotherapy cancer treatment work together to treat your child’s cancer.

Treating Your Child’s Cancer with Precision Medicine

Dr. Ashley Plant, pediatric oncologist, discusses treating your child’s cancer with precision medicine, tailoring medical treatment to the individual genetic characteristics of each patient’s disease.

Understanding and Treating Recurrent and Refractory Cancers

Dr. Van Huynh, pediatric oncologist, discusses what it means when your child has recurrent or refractory cancer and the treatments available.

Oncology Clinical Trial: Childhood Cancer Survivor Study

Clinical Trial | Survivorship | Contact (714) 509-8646

When a Child Has Plastic Surgery After Cancer Treatment

Dr. Raj Vyas explains how cancer treatment can cause a physical defect that requires reconstructive surgery to repair.

Oncology Clinical Trial: Approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer.

Clinical Trial | Survivorship | Contact (714) 509-8646

Oncology Clinical Trial: Can Video Testimonials Benefit Adolescents with Cancer?

Clinical Trial | Adolescents and Young Adults, Supportive Care | Contact (714) 509-8646

Oncology Clinical Trial: Fertility Preservation in Women and Girls with Cancer

Clinical Trial | Adolescents and Young Adults, Fertility, Survivorship | Contact (714) 509-8646

Oncology Clinical Trial: Project – Every Child for Younger Patients With Cancer

Clinical Trial Protocol # APEC14B1 | Biology/Genomics, Registry | Contact (714) 509-8646

Breaking Barriers in Acute Lymphoblasic Luekemia (ALL)

This year, the conference, titled "Breaking Barriers in Acute Lymphoblastic Leukemia," focused, as the name implies, specifically on all aspects of acute lymphoblastic leukemia (ALL).

Torno, Lilibeth L. MD

Dr. Torno is a CHOC Specialist in pediatric oncology and the medical director of the After Cancer Treatment Survivorship (ACTS) Program.

Oncology Clinical Trial: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

Clinical Trial Protocol # MK3475-051/ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma

Clinical Trial Protocol # ADVL1513 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

AHOD1721/BMS CA209744 – Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after

Clinical Trial Protocol # AHOD1721 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Clinical Trial Protocol # ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Kids and Melanoma

Orange County is one of the sunniest places in California, with hundreds of sun days per year. With that comes the need for proper protection.

Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

Phase 1 Study of ABI-009 (nab-rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan

Clinical Trial Protocol # ADVL1514 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646